Jakub Kucharz

1.1k total citations · 1 hit paper
47 papers, 575 citations indexed

About

Jakub Kucharz is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Jakub Kucharz has authored 47 papers receiving a total of 575 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Pulmonary and Respiratory Medicine, 18 papers in Oncology and 15 papers in Molecular Biology. Recurrent topics in Jakub Kucharz's work include Renal cell carcinoma treatment (19 papers), Renal and related cancers (9 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Jakub Kucharz is often cited by papers focused on Renal cell carcinoma treatment (19 papers), Renal and related cancers (9 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Jakub Kucharz collaborates with scholars based in Poland, Hungary and Spain. Jakub Kucharz's co-authors include Paulina Dumnicka, Beata Kuśnierz‐Cabala, Paweł Wiechno, Tomasz Demkow, Krzysztof Krzemieniecki, R. M. Herman, Matteo Rosellini, Andrey Soares, Elisa Tassinari and Javier Molina‐Cerrillo and has published in prestigious journals such as Journal of Clinical Oncology, Molecules and European Urology.

In The Last Decade

Jakub Kucharz

44 papers receiving 569 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis

2023 117 citations Matteo Santoni, Jakub Kucharz et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jakub Kucharz Poland	12	226	173	129	101	64	47	575
Yıldız Okuturlar Türkiye	13	149 0.7×	70 0.4×	103 0.8×	94 0.9×	72 1.1×	55	475
Young‐Woong Won South Korea	16	266 1.2×	272 1.6×	147 1.1×	66 0.7×	62 1.0×	58	681
İbrahim Yıldız Türkiye	14	127 0.6×	193 1.1×	82 0.6×	68 0.7×	59 0.9×	69	505
Xinjun Liang China	13	212 0.9×	66 0.4×	114 0.9×	61 0.6×	86 1.3×	46	528
Josephina G. Kuiper Netherlands	13	182 0.8×	110 0.6×	63 0.5×	87 0.9×	50 0.8×	37	640
Ravi Kumar Paluri United States	15	326 1.4×	140 0.8×	112 0.9×	117 1.2×	65 1.0×	64	684
Κonstantinos Romanidis Greece	13	237 1.0×	164 0.9×	113 0.9×	175 1.7×	79 1.2×	55	594
Jennifer Obel United States	14	358 1.6×	105 0.6×	107 0.8×	57 0.6×	84 1.3×	23	659
Michael W. Lee United States	15	107 0.5×	178 1.0×	288 2.2×	116 1.1×	70 1.1×	41	823
Kazuko Nishio Japan	16	231 1.0×	46 0.3×	160 1.2×	143 1.4×	99 1.5×	37	812

Countries citing papers authored by Jakub Kucharz

Since Specialization

Citations

This map shows the geographic impact of Jakub Kucharz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jakub Kucharz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jakub Kucharz more than expected).

Fields of papers citing papers by Jakub Kucharz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jakub Kucharz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jakub Kucharz. The network helps show where Jakub Kucharz may publish in the future.

Co-authorship network of co-authors of Jakub Kucharz

This figure shows the co-authorship network connecting the top 25 collaborators of Jakub Kucharz. A scholar is included among the top collaborators of Jakub Kucharz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jakub Kucharz. Jakub Kucharz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kucharz, Jakub, Alexandr Poprach, Bożena Sikora-Kupis, et al.. (2025). Cabozantinib in the First-Line Treatment of Patients With Metastatic Renal Cell Carcinoma, Real-World Data From the Czech Republic and Poland: ICARO-RC Project. Clinical Genitourinary Cancer. 23(4). 102382–102382.

Wysocki, Piotr J., et al.. (2025). Optimization of systemic treatment in patients with bladder, ureter, and renal pelvis cancer — expert opinion of the Polish Society of Clinical Oncology. Oncology in Clinical Practice. 21(3). 177–192. 1 indexed citations

Demkow, Tomasz, et al.. (2025). Longitudinally extensive transverse myelitis after pembrolizumab and lenvatinib therapy for a rare subtype of renal cell carcinoma: A case report. Oncology Letters. 30(2). 1–6.

Orzechowska, Magdalena, et al.. (2024). High FLT3 expression increases immune‐cell infiltration in the tumor microenvironment and correlates with prolonged disease‐free survival in patients with non‐small cell lung cancer. Molecular Oncology. 18(5). 1316–1326. 6 indexed citations

Demkow, Tomasz, et al.. (2024). Adverse Events of Cabozantinib as a Potential Prognostic Factor in Metastatic Renal Cell Carcinoma Patients: Real-World Experience in a Single-Center Retrospective Study. Biomedicines. 12(2). 413–413. 1 indexed citations

Demkow, Tomasz, et al.. (2024). Analysis of Factors Contributing to Adverse Events and Evaluation of Their Impact on Prognosis in Metastatic Renal Cell Carcinoma Patients—Real-World Experience in a Single-Center Retrospective Study and Narrative Review. Medicina. 60(3). 398–398. 1 indexed citations

Saracyn, Marek, et al.. (2024). Theranostics in Renal Cell Carcinoma—A Step Towards New Opportunities or a Dead End—A Systematic Review. Pharmaceuticals. 17(12). 1721–1721. 1 indexed citations

Monteiro, Fernando Sabino Marques, Ondřej Fiala, Francesco Massari, et al.. (2023). Systemic Immune-Inflammation Index in Patients Treated With First-Line Immune Combinations for Metastatic Renal Cell Carcinoma: Insights From the ARON-1 Study. Clinical Genitourinary Cancer. 22(2). 305–314.e3. 4 indexed citations

Demkow, Tomasz, et al.. (2023). Activity of cabozantinib in further line treatment of metastatic clear cell renal cell carcinoma. Real-world experience in a single-center retrospective study. Współczesna Onkologia. 27(3). 190–197. 2 indexed citations

10.

Sikora-Kupis, Bożena, et al.. (2023). First experience in treating advanced urothelial cancer with enfortumab vedotin. Single-centre retrospective study of patients qualified for a rescue access procedure. Współczesna Onkologia. 27(4). 224–229. 1 indexed citations

11.

Stawiski, Konrad, et al.. (2020). Dose–volume parameters of MRI-based active bone marrow predict hematologic toxicity of chemoradiotherapy for rectal cancer. Strahlentherapie und Onkologie. 196(11). 998–1005. 14 indexed citations

12.

Michalski, Wojciech, Jakub Kucharz, Joanna Jońska‐Gmyrek, et al.. (2020). What is the damage? Testicular germ cell tumour survivors deficient in testosterone at risk of metabolic syndrome and a need for medical intervention. Medical Oncology. 37(9). 82–82. 4 indexed citations

13.

Kucharz, Jakub, Monika Budnik, Paulina Dumnicka, et al.. (2019). Hand-Foot Syndrome and Progression-Free Survival in Patients Treated with Sunitinib for Metastatic Clear Cell Renal Cell Carcinoma. Advances in experimental medicine and biology. 1133. 35–40. 7 indexed citations

14.

Dumnicka, Paulina, Beata Kuśnierz‐Cabala, Agnieszka Gala‐Błądzińska, et al.. (2018). Markers of Glomerular and Tubular Damage in the Early Stage of Kidney Disease in Type 2 Diabetic Patients. Mediators of Inflammation. 2018. 1–12. 70 indexed citations

15.

Krzemieniecki, Krzysztof, et al.. (2018). Better compliance with the guidelines on hand-foot syndrome in patients treated with capecitabine in colorectal and breast cancer as a result of nursing education.. PubMed. 73(7). 460–4. 2 indexed citations

16.

Pastuszczak, Maciej, et al.. (2018). Lack of antiretroviral therapy is associated with higher risk of neurosyphilis among HIV-infected patients who remain serofast after therapy for early syphilis. Medicine. 97(45). e13171–e13171. 14 indexed citations

17.

Wiechno, Paweł, Jakub Kucharz, Wojciech Michalski, et al.. (2018). Contemporary treatment of metastatic renal cell carcinoma. Medical Oncology. 35(12). 156–156. 40 indexed citations

18.

Michalski, Wojciech, et al.. (2018). Testicular teratomas: a growing problem?. Medical Oncology. 35(12). 153–153. 5 indexed citations

19.

Krzyżewski, Roger M., Jakub Kucharz, Anna Maria Michałowska‐Kaczmarczyk, et al.. (2017). High-dose 8% capsaicin patch in treatment of chemotherapy-induced peripheral neuropathy: single-center experience. Medical Oncology. 34(9). 162–162. 40 indexed citations

20.

Kucharz, Jakub, Paulina Dumnicka, Marek Kuźniewski, et al.. (2017). Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients. Medical Oncology. 34(4). 68–68. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact